Patents by Inventor Dongjiang CHEN

Dongjiang CHEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for restoring sensitivity to TTFields in TTFields-resistant cancer cells with PTGER3 inhibitors
    Patent number: 11911610
    Abstract: Methods of reducing the viability of cancer cells, preventing cancer cells of a subject from developing resistance to TTFields, and restoring sensitivity of cancer cells to TTFields by recommending or prescribing a PTGER3 inhibitor to a subject and applying an alternating electric field to the cancer cells are provided. In some instances, sensitivity of cancer cells to TTFields can be restored with one or more PTGER3 inhibitors (e.g., NSAIDs, cox2 inhibitors).
    Type: Grant
    Filed: March 27, 2020
    Date of Patent: February 27, 2024
    Assignee: Novocure GmbH
    Inventors: David Tran, Son Bang Le, Dongjiang Chen
  • Methods and Compositions for Determining Susceptibility to Treatment with Checkpoint Inhibitors
    Publication number: 20220267445
    Abstract: Methods and kits treating a subject with a checkpoint inhibitor are provided by detecting expression levels of one or more biomarkers (e.g., cytokines and cytotoxic genes, immune cell functional regulators, naïve immune cell markers, regulatory T cell factors, and immune inhibitory receptors) in immune cells of a patient or subject with a condition (e.g., cancer) before and after exposure of tumor cells to alternating electric fields. Kits comprising nucleic acid probes for detecting the one or more biomarkers are also provided.
    Type: Application
    Filed: February 16, 2022
    Publication date: August 25, 2022
    Applicant: Novocure GmbH
    Inventors: David TRAN, Dongjiang Chen
  • Methods for Reducing Viability of Cancer Cells by Activation of the STING Pathway with TTFields
    Publication number: 20210069503
    Abstract: Viability of cancer cells (e.g., glioblastoma cells) can be reduced by applying an alternating electric field with a frequency between 100 and 500 kHz to the cancer cells for about 3-10 days and administering a checkpoint inhibitor to the cancer cells.
    Type: Application
    Filed: November 4, 2019
    Publication date: March 11, 2021
    Inventors: David TRAN, Dongjiang CHEN
  • Methods for Restoring Sensitivity to TTFields in TTFields-Resistant Cancer Cells with PTGER3 Inhibitors
    Publication number: 20200306531
    Abstract: Methods of reducing the viability of cancer cells, preventing cancer cells of a subject from developing resistance to TTFields, and restoring sensitivity of cancer cells to TTFields by recommending or prescribing a PTGER3 inhibitor to a subject and applying an alternating electric field to the cancer cells are provided. In some instances, sensitivity of cancer cells to TTFields can be restored with one or more PTGER3 inhibitors (e.g., NSAIDs, cox2 inhibitors).
    Type: Application
    Filed: March 27, 2020
    Publication date: October 1, 2020
    Applicant: Novocure GmbH
    Inventors: David TRAN, Son Bang LE, Dongjiang CHEN